Waters (WAT) Stock
Global lab instrument maker for drug development and testing. Here's the price, business snapshot, and what's worth knowing about Waters in August 2026.
Waters Corporation (WAT) designs and manufactures laboratory analytical instruments — notably high-performance liquid chromatography and mass spectrometry systems — used to separate, identify and quantify chemical compounds. Its products, consumables and services serve pharmaceutical, biotech, chemical, food-safety and environmental laboratories worldwide. Revenue typically comprises capital equipment sales and recurring aftermarket consumables and service contracts, which can provide resilient cash flow but remain sensitive to capital spending cycles. Waters benefits from a strong installed base, long product lifecycles and regulatory-driven demand in drug development and quality control. Key considerations for investors include exposure to global pharmaceutical investment, competition from other instrument makers, currency and supply-chain risks, and the ongoing need for R&D. Market cap: $20.79B. This is general information for education, not personalised advice; values can rise or fall and past performance is not a guide.
Why It’s Moving
Waters rises as a stronger-than-expected quarter and higher outlook sharpen the growth story.
- Waters’ Aug. 4 second-quarter results beat expectations, showing that demand for its lab equipment and newly acquired diagnostics businesses is still holding up better than many investors feared.
- Management raised full-year 2026 guidance, signaling confidence that the recent acquisition integration and organic growth trends are improving the company’s earnings power.
- The stock has also been reacting to the broader healthcare/life-science tools backdrop, where investors are rewarding companies that can show steady demand, margin discipline, and clear payoff from acquisitions.
Waters rises as a stronger-than-expected quarter and higher outlook sharpen the growth story.
- Waters’ Aug. 4 second-quarter results beat expectations, showing that demand for its lab equipment and newly acquired diagnostics businesses is still holding up better than many investors feared.
- Management raised full-year 2026 guidance, signaling confidence that the recent acquisition integration and organic growth trends are improving the company’s earnings power.
- The stock has also been reacting to the broader healthcare/life-science tools backdrop, where investors are rewarding companies that can show steady demand, margin discipline, and clear payoff from acquisitions.
Sixth Month Growth Performance
next-earnings-question
Waters Corporation’s next earnings date is currently estimated for November 3, 2026. The report should cover the third quarter of 2026. This date is based on the company’s historical reporting pattern and has not yet been formally confirmed.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Waters Corporation's stock with a target price of $372.85, indicating growth potential.
Financial Health
Waters Corporation is performing well with strong revenue, profits, and cash flow generation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Aftermarket Revenue Strength
Consumables and service contracts create steady recurring income that can stabilise revenue, though instrument orders remain cyclical and can vary.
Pharma & Regulation Demand
Demand from drug development and regulatory testing supports long-term need for high-end instruments, but exposure to regulatory cycles and geographic shifts adds variability.
Innovation & Competition
Continued R&D keeps the product line competitive in high-precision analytics, yet heavy R&D spend and rival technologies present execution risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
